Jørgen Nordling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jørgen Nordling has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Magnus Fall
Department of Urology, Institute of Clinical Sciences Sahlgrenska Academy at the University of Gothenburg Göteborg Sweden
4 shared publications Magnus Fall
Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden
3 shared publicationsPhilip Hanno
Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
3 shared publicationsAndrew Zaitcev
Department of Urology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
2 shared publicationsHikaru Tomoe
Department of Urology, Tokyo Women's Medical University Medical Center East Tokyo, Japan, Tokyo, Japan
2 shared publicationsJane Meijlink
International Painful Bladder Foundation, Narden, The Netherlands
2 shared publications
Latest Publications
- 26 June 2020
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (4) , 355-356
Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99–100; https://doi.org/10.1080/21681805.2020.1744714
(2020). Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99–100; https://doi.org/10.1080/21681805.2020.1744714. Scandinavian Journal of Urology. Ahead of Print.
- 26 June 2020
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (4) , 355-356
Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99–100; https://doi.org/10.1080/21681805.2020.1744714
(2020). Comments to Editorial by J. Curtis Nickel. It is premature to categorize Hunner lesion interstitial cystitis as a distinct disease entity. Scandinavian Journal of Urology 2020, Vol. 54, No. 2, 99–100; https://doi.org/10.1080/21681805.2020.1744714. Scandinavian Journal of Urology. Ahead of Print.
- 28 February 2020
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (2) , 91-98
Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report
Objectives: There is confusion about the terms of bladder pain syndrome (BPS) and Interstitial Cystitis (IC). The European Society for the Study of IC (ESSIC) classified these according to objective findings [ 9 van de Merwe JP , Nordling J , Bouchelouche P , et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–67. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ]. One phenotype, Hunner lesion disease (HLD or ESSIC 3C) differs markedly from other presentations. Therefore, the question was raised as to whether this is a separate condition or BPS subtype. Methods: An evaluation was made to explore if HLD differs from other BPS presentations regarding symptomatology, physical examination findings, laboratory tests, endoscopy, histopathology, natural history, epidemiology, prognosis and treatment outcomes. Results: Cystoscopy is the method of choice to identify Hunner lesions, histopathology the method to confirm it. You cannot distinguish between main forms of BPS by means of symptoms, physical examination or laboratory tests. Epidemiologic data are incomplete. HLD seems relatively uncommon, although more frequent in older patients than non-HLD. No indication has been presented of BPS and HLD as a continuum of conditions, one developing into the other. Conclusions: A paradigm shift in the understanding of BPS/IC is urgent. A highly topical issue is to separate HLD and BPS: treatment results and prognoses differ substantially. Since historically, IC was tantamount to Hunner lesions and interstitial inflammation in the bladder wall, still, a valid definition, the term IC should preferably be reserved for HLD patients. BPS is a symptom syndrome without specific objective findings and should be used for other patients fulfilling the ESSIC definitions.
- 28 February 2020
- Published by Medical Journals Sweden AB in Scandinavian Journal of Urology
- Vol. 54 (2) , 91-98
Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report
Objectives: There is confusion about the terms of bladder pain syndrome (BPS) and Interstitial Cystitis (IC). The European Society for the Study of IC (ESSIC) classified these according to objective findings [ 9 van de Merwe JP , Nordling J , Bouchelouche P , et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–67. [Crossref], [PubMed], [Web of Science ®] , [Google Scholar] ]. One phenotype, Hunner lesion disease (HLD or ESSIC 3C) differs markedly from other presentations. Therefore, the question was raised as to whether this is a separate condition or BPS subtype. Methods: An evaluation was made to explore if HLD differs from other BPS presentations regarding symptomatology, physical examination findings, laboratory tests, endoscopy, histopathology, natural history, epidemiology, prognosis and treatment outcomes. Results: Cystoscopy is the method of choice to identify Hunner lesions, histopathology the method to confirm it. You cannot distinguish between main forms of BPS by means of symptoms, physical examination or laboratory tests. Epidemiologic data are incomplete. HLD seems relatively uncommon, although more frequent in older patients than non-HLD. No indication has been presented of BPS and HLD as a continuum of conditions, one developing into the other. Conclusions: A paradigm shift in the understanding of BPS/IC is urgent. A highly topical issue is to separate HLD and BPS: treatment results and prognoses differ substantially. Since historically, IC was tantamount to Hunner lesions and interstitial inflammation in the bladder wall, still, a valid definition, the term IC should preferably be reserved for HLD patients. BPS is a symptom syndrome without specific objective findings and should be used for other patients fulfilling the ESSIC definitions.
- 16 August 2017
- Published by Springer Nature
- p. 37-39
Etiology: Etiological and Pathogenic Theories of Interstitial Cystitis/Bladder Pain Syndrome
- 16 August 2017
- Published by Springer Nature
- p. 37-39
Etiology: Etiological and Pathogenic Theories of Interstitial Cystitis/Bladder Pain Syndrome
- 6 June 2017
- Published by Springer Nature
- p. 359-364
Cystectomy/Supravesical Diversion for Interstitial Cystitis
- 6 June 2017
- Published by Springer Nature
- p. 359-364
Cystectomy/Supravesical Diversion for Interstitial Cystitis
- 10 October 2012
- Published by Springer Nature
- p. 21-33
Diagnostic Criteria, Classification and Nomenclature for Bladder Pain Syndrome
- 10 October 2012
- Published by Springer Nature
- p. 21-33
Diagnostic Criteria, Classification and Nomenclature for Bladder Pain Syndrome
- 10 October 2012
- Published by Springer Nature
- p. 343-352
Bladder Augmentation, Urinary Diversion and Cystectomy in Patients with Bladder Pain Syndrome
- 10 October 2012
- Published by Springer Nature
- p. 343-352
Bladder Augmentation, Urinary Diversion and Cystectomy in Patients with Bladder Pain Syndrome
- 10 October 2012
- Published by Springer Nature
- p. 317-320
Hydrodistention, Transurethral Resection and Other Ablative Techniques in the Treatment of Bladder Pain Syndrome
- 10 October 2012
- Published by Springer Nature
- p. 317-320
Hydrodistention, Transurethral Resection and Other Ablative Techniques in the Treatment of Bladder Pain Syndrome
- 5 November 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (4) , 457-464
Global concepts of bladder pain syndrome (interstitial cystitis)
Bladder pain syndrome (BPS), commonly referred to as “interstitial cystitis”, is no longer considered a rare disorder. It may affect up to 2.7% of the adult female population (Ueda et al. in Int J Urol 10:1–70, 2003) with up to 20% of cases occurring in men. The last two decades have seen a worldwide effort to try to standardize its nomenclature, definition, diagnosis, and treatment algorithm. The literature has been reviewed. In this article, we will detail current terminology, diagnostic approaches and treatment. Standard therapies will be discussed, and a section that concentrates on the management of the subset of patients with a Hunner’s lesion will be highlighted. BPS is today viewed through a new paradigm. It is no longer considered primarily a bladder disease, but rather one of a number of chronic pain syndromes that is distinguished by being manifest through bladder-related symptoms. A distinct subgroup of patients with Hunner’s lesion has specific characteristics, and successful treatment of this subgroup is available.
- 5 November 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 30 (4) , 457-464
Global concepts of bladder pain syndrome (interstitial cystitis)
Bladder pain syndrome (BPS), commonly referred to as “interstitial cystitis”, is no longer considered a rare disorder. It may affect up to 2.7% of the adult female population (Ueda et al. in Int J Urol 10:1–70, 2003) with up to 20% of cases occurring in men. The last two decades have seen a worldwide effort to try to standardize its nomenclature, definition, diagnosis, and treatment algorithm. The literature has been reviewed. In this article, we will detail current terminology, diagnostic approaches and treatment. Standard therapies will be discussed, and a section that concentrates on the management of the subset of patients with a Hunner’s lesion will be highlighted. BPS is today viewed through a new paradigm. It is no longer considered primarily a bladder disease, but rather one of a number of chronic pain syndromes that is distinguished by being manifest through bladder-related symptoms. A distinct subgroup of patients with Hunner’s lesion has specific characteristics, and successful treatment of this subgroup is available.
- 7 July 2011
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 6 (3) , 116-127
Bladder Pain Syndrome, Interstitial Cystitis, Painful Bladder Syndrome, and Hypersensitive Bladder Syndrome: New Nomenclature/New Guidelines
- 7 July 2011
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 6 (3) , 116-127
Bladder Pain Syndrome, Interstitial Cystitis, Painful Bladder Syndrome, and Hypersensitive Bladder Syndrome: New Nomenclature/New Guidelines
- 1 July 2008
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 58 (07) , 328-335
Intravesical Glycosaminoglycan Replenishment with Chondroitin Sulphate in Chronic Forms of Cystitis
Effectiveness, safety, and tolerability of instillation therapy with chondroitin sulphate (CAS 9082-07-9, Gepan® instill) was investigated in a non-interventional study. 286 patients with clinically diagnosed chronic forms of cystitis, such as bladder pain syndrome/interstitial cystitis, radiation cystitis, overactive bladder syndrome and chronically-recurring cystitis were included. The course of symptoms was documented over 8 instillations at maximum, covering a period of approximately three months. All main symptoms of chronic cystitis declined consistently and statistically significantly (p < 0.0001). Both daytime and nighttime micturition frequencies as well as the score levels of urgency and pain declined significantly during the course of treatment. The functional bladder capacity as indicated by the volume of first morning voiding increased from 157.9 ml ± 7.5 to 186.7 ml ± 6.9 (mean ± SE; p < 0.0001). The level of urgency decreased from 6.8 ± 0.1 to 3.4 ± 0.2 (mean ± SE; numerical rating scale (11-point box scale); p < 0.0001) and nocturia decreased from 4.0 ± 0.2 to 2.1 ± 0.1 times (mean ± SE; p < 0.0001). Chondroitin sulphate instillation was effective and well tolerated in the therapy of chronic forms of cystitis associated with a possible GAG layer deficit (GAG layer: mainly composed of the glycosaminoglycans chondroitin sulphate, dermatan sulphate and heparan sulphate), but the results need to be confirmed in a controlled study.
- 1 July 2008
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 58 (07) , 328-335
Intravesical Glycosaminoglycan Replenishment with Chondroitin Sulphate in Chronic Forms of Cystitis
Effectiveness, safety, and tolerability of instillation therapy with chondroitin sulphate (CAS 9082-07-9, Gepan® instill) was investigated in a non-interventional study. 286 patients with clinically diagnosed chronic forms of cystitis, such as bladder pain syndrome/interstitial cystitis, radiation cystitis, overactive bladder syndrome and chronically-recurring cystitis were included. The course of symptoms was documented over 8 instillations at maximum, covering a period of approximately three months. All main symptoms of chronic cystitis declined consistently and statistically significantly (p < 0.0001). Both daytime and nighttime micturition frequencies as well as the score levels of urgency and pain declined significantly during the course of treatment. The functional bladder capacity as indicated by the volume of first morning voiding increased from 157.9 ml ± 7.5 to 186.7 ml ± 6.9 (mean ± SE; p < 0.0001). The level of urgency decreased from 6.8 ± 0.1 to 3.4 ± 0.2 (mean ± SE; numerical rating scale (11-point box scale); p < 0.0001) and nocturia decreased from 4.0 ± 0.2 to 2.1 ± 0.1 times (mean ± SE; p < 0.0001). Chondroitin sulphate instillation was effective and well tolerated in the therapy of chronic forms of cystitis associated with a possible GAG layer deficit (GAG layer: mainly composed of the glycosaminoglycans chondroitin sulphate, dermatan sulphate and heparan sulphate), but the results need to be confirmed in a controlled study.